Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 30Docetaxel 10Cetuximab 10Trastuzumab 9Paclitaxel 7Nivolumab 6Magnetic Resonance Spectroscopy 6palbociclib 5cemiplimab 5Gemcitabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5Biopsy 5durvalumab 4atezolizumab 4Surveys and Questionnaires 4Radiotherapy 4Fulvestrant 4Fluorodeoxyglucose F18 4Drug Therapy 4Cisplatin 4selpercatinib 3poly ICLC 3pazopanib 3fludarabine 3avelumab 3Taxes 3Sunitinib 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Lutetium × Head & Neck × Clear all
NCT07274852 2026-01-06

A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1 Recruiting
22 enrolled
BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡